

AMENDMENTS TO THE SPECIFICATION:

Please add the following paragraph at page after the title as follows:

Cross Reference To Related Application

This application is a 371 national phase of PCT/CN2004/000645, filed June 17, 2004, which claims priority of CN03142873.8 filed June 17, 2003.

Please amend the paragraph beginning on page 8, line 19 as follows:

1st group of primers: upstream primer 5' ACA GGA TCC AAG AAC ATG TTT ATT TTC TTA TT 3' (SEQ ID NO: 16), downstream primer 5' AGA TCT GAA TTC TAT CCA ATA GGA ATG TCG CAC TC 3' (SEQ ID NO:17);

2nd group of primers: upstream primer 5' ATT GGA TCC ACC ATG GGC TGT CTT ATA GGA GCT GAG C 3'(SEQ ID NO: 18), downstream primer 5' ATG GAT CCG AAT TCT GGC TGT GCA GTA ATT GAT CT 3'(SEQ ID NO: 19);

3rd group of primers: upstream primer 5' CAA GGA TCC GTT ATG TAC TCA TTC GTT TCG 3'(SEQ ID NO: 20), downstream primer 5' ACA AGA TCT GAA TTC TTT AAG CTC CTC AAC GGT AA 3'(SEQ ID NO: 21);

4th group of primers: upstream primer 5' ACA GGA TCC ATC ATG GCA GAC AAC GGT AC 3'(SEQ ID NO: 22), downstream primer 5' AAC AGA TCT GAA TTC GCA ATC CTG AAA GTC CTC ATA 3'(SEQ ID NO: 23);

5th group of primers: upstream primer 5' ATT GGA TCC GTC ATG GAC AAT AAC CAG AAT GGA GGA CG 3'(SEQ ID NO: 24), downstream primer 5' AAC AGA TCT GAA TTC ATT CTG CAC AAG AG 3' (SEQ ID NO: 25);

6th group of primers: upstream primer 5' ACA CCA TGG AAT TCG ACA TGG CTA TTT CAC CGA AG 3' (SEQ ID NO: 26), downstream primer 5' CAG GTA CCG GAT CCA ATA TTG CAG CAG TAC GCA C 3' (SEQ ID NO: 27).

Please amend the paragraph beginning on page 11, line 21 as follows:

The inventor noted that the translated product of SEQ ID NO:1 could cause immunological reactions. Any translation product of SEQ ID NO:1 was included in the invention. The translation products of SEQ ID NO:1, with different start site are also included in the invention. The whole amino acid sequence translated from SEQ ID NO:1 was recorded as ~~SEQ ID NO:8~~SEQ ID NOS: 8, 28-37.

Please amend the paragraph beginning on page 12, line 3 as follows:

The isolated polypeptide in the invention included the following amino acid sequences:

- a) ~~SEQ ID NO:8~~SEQ ID NOS: 8, 28-37;
- b) a naturally-occurring amino acid sequence having at least 90% sequence identity to any of the sequence of ~~SEQ ID NO:8~~SEQ ID NOS: 8, 28-37;
- c) a biologically-active fragment of any of the amino acid sequence of ~~SEQ ID NO:8~~SEQ ID NOS: 8, 28-37; and
- d) an immunogenic fragment of any of the amino acid sequence of ~~SEQ ID NO:8~~SEQ ID NOS: 8, 28-37.

Please amend the paragraph beginning on page 14, line 10 as follows:

An isolated polynucleotide sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:

- a. ~~SEQ ID NO:8~~SEQ ID NOS: 8, 28-37;

- b. a naturally-occurring amino acid sequence having at least 90% sequence identity to any of the sequence of SEQ ID NO: 8 SEQ ID NOS: 8, 28-37;
- c. a biologically-active fragment of any of the amino acid sequence of ~~SEQ ID NO: 8~~ SEQ ID NOS: 8, 28-37; and
- d. an immunogenic fragment of any of the amino acid sequence of ~~SEQ ID NO: 8~~ SEQ ID NOS: 8, 28-37.

Please amend the paragraph beginning on page 14, line 26 as follows:

An isolated polypeptide sequence comprising an amino acid sequence selected from the group consisting of:

- a) an amino acid sequence of any of ~~SEQ ID NO: 8~~ SEQ ID NOS: 8, 28-37;
- b) a naturally-occurring amino acid sequence having at least 90% sequence identity to any of the amino acid sequence of ~~SEQ ID NO: 8~~ SEQ ID NOS: 8, 28-37;
- c) a biologically active fragment of any of the amino acid sequence of ~~SEQ ID NO: 8~~ SEQ ID NOS: 8, 28-37; and
- d) an immunogenic fragment of any of the amino acid sequence of ~~SEQ ID NO: 8~~ SEQ ID NOS: 8, 28-37.